Visugromab überwindet Resistenz gegen Krebsimmuntherapie - BZKF

Würzburg, 14.07.2026

You are now leaving the website for patients and interested parties and will be redirected to our page for healthcare professionals at
.

Specialist groups

Would you like to stay on our page for affected and interested parties ?